The present invention describes combination treatment comprising a PD-1 axis binding antagonist, oxaliplatin, leucovorin and 5-FU, and optionally a VEGF antagonist, and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired, such as increasing tumor immunogenicity for the treatment of cancer.